股本结构
单位：万股
| 公告日期 | 2024-04-15 | 2024-03-29 | 2024-03-29 | 2024-04-15 | 2024-01-08 | 2024-04-01 |
|---|---|---|---|---|---|---|
| 证券总股本 | 9554.38 | 8449.09 | 7372.42 | 7061.52 | 8081.64 | 5861.46 |
| 普通股本 | 9554.38 | 8449.09 | 7372.42 | 7061.52 | 8081.64 | 5861.46 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-04-12 | 2024-04-01 | 2024-03-27 | 2024-03-25 | 2024-01-05 | 2023-12-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-04-15 | 9554.38 | 未披露 | 定期报告 | 2024-04-12 |
| 2024-03-29 | 8449.09 | 未披露 |
更多>>
Common stock offered 10,766,666 shares by the company
|
2024-04-01 |
| 2024-03-29 | 7372.42 | 未披露 | 定期报告 | 2024-03-27 |
| 2024-04-15 | 7061.52 | 未披露 | 定期报告 | 2024-03-25 |
| 2024-01-08 | 8081.64 | 未披露 | 定期报告 | 2024-01-05 |
| 2024-04-01 | 5861.46 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Repurchase of common stock under Share Repurchase Program, including transactional expenses of $334
Issuance of common stock under 2022 Purchase agreement
Issuance of common stock under At-the-market offering, net of transactional expenses of $137
Issuance of common stock and warrants under AGP Financing, net of transactional expenses of $2,663
Issuance of common stock upon exercise of prefunded common warrants
Employee stock purchase plan
|
2023-12-31 |
| 2023-12-26 | 5861.46 | 未披露 |
更多>>
Common stock offered 25,343,242 shares by the company
|
2023-12-22 |
| 2023-12-21 | 2676.23 | 未披露 | 定期报告 | 2023-12-19 |
| 2023-11-09 | 2384.93 | 未披露 | 定期报告 | 2023-11-09 |
| 2023-09-29 | 2181.23 | 未披露 |
更多>>
Common Stock offered 4,050,000 shares by the company
|
2023-10-03 |
| 2023-11-09 | 1776.23 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock under AGP Financing, net of transactional expenses of $726
Issuance of common stock upon exercise of prefunded warrants under AGP Financing
|
2023-09-30 |
| 2023-08-10 | 1776.23 | 未披露 | 定期报告 | 2023-08-09 |
| 2023-07-28 | 1329.23 | 未披露 |
更多>>
Common Stock offered 2,530,000 shares of Common Stock by the company
|
2023-08-01 |
| 2023-08-10 | 1076.23 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock net of transactional expenses of $36
|
2023-06-30 |
| 2023-05-09 | 1034.04 | 未披露 |
更多>>
Tonix Pharmaceuticals Holding Corp. announced that it will effect a 1-for-6.25 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on May 10, 2023.
|
2023-05-10 |
| 2023-05-08 | 6462.72 | 未披露 | 定期报告 | 2023-05-08 |
| 2023-05-08 | 6368.77 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Repurchase of common stock under share repurchase program, including transactional expenses of $334
Issuance of common stock under 2022 Purchase agreement with Lincoln Park
Issuance of common stock net of transactional expenses of $101
Employee stock purchase plan
|
2023-03-31 |
| 2023-03-17 | 6266.39 | 未披露 | 定期报告 | 2023-03-17 |
| 2023-03-13 | 6253.95 | 未披露 | 定期报告 | 2023-03-13 |
| 2023-03-13 | 7647.87 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock under At-the-market offering, net of transactional expenses of $3,078
Issuance of common stock under 2022 Purchase Agreement
Issuance of common stock under 2021 Purchase Agreement
Issuance of commitment shares under 2022 Purchase agreement
Employee stock purchase plan
|
2022-12-31 |
| 2022-11-07 | 5753.63 | 未披露 | 定期报告 | 2022-11-04 |
| 2022-11-07 | 5697.90 | 150.00 | 定期报告 | 2022-10-28 |
| 2022-10-21 | 5575.27 | 未披露 | 定期报告 | 2022-10-20 |
| 2022-11-07 | 5332.15 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock under the 2021 Purchase agreement
Issuance of common stock in July, August and September 2022 under At-the-market offering, net of transactional expenses of $805
Issuance of commitment shares under 2022 Purchase Agreement
|
2022-09-30 |
| 2022-08-19 | 4479.59 | 未披露 | 定期报告 | 2022-08-18 |
| 2022-08-17 | 4417.09 | 未披露 | 定期报告 | 2022-08-16 |
| 2022-08-08 | 4306.11 | 未披露 | 定期报告 | 2022-08-08 |
| 2022-07-29 | 3586.20 | 未披露 | 定期报告 | 2022-07-29 |
| 2022-07-05 | 3169.20 | 300.00 | 定期报告 | 2022-06-28 |
| 2022-05-16 | 1874.00 | 未披露 |
更多>>
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on May 17, 2022.
|
2022-05-17 |
| 2022-05-09 | 59967.96 | 未披露 | 定期报告 | 2022-05-09 |
| 2022-05-09 | 55282.74 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock in January and March 2022, net of transactional expenses of $507
Issuance of common stock under Purchase agreement with Lincoln Park
Employee stock purchase plan
|
2022-03-31 |
| 2022-03-18 | 53392.86 | 未披露 | 定期报告 | 2022-03-11 |
| 2022-03-14 | 49624.56 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock in January 2021($0.80 per share), net of transactional expenses of $3,096
Issuance of common stock in exchange for exercise of warrants in March 2021 ($0.57 per share)
Issuance of common stock in February 2021($1.20 per share), net of transactional expenses of $5,002
Issuance of common stock under At-the-market offering, net of transactional expenses of $2,332
Issuance of common stock under 2021 Purchase Agreement, net of transactional expenses of $75
Issuance of commitment shares under 2021 Purchase agreement
Issuance of common stock in the acquisition of the OyaGen license
Issuance of commitment shares under Lincoln park Purchase agreement
Employee stock purchase plan
|
2021-12-31 |
| 2021-12-03 | 47133.79 | 未披露 | 定期报告 | 2021-12-02 |
| 2021-11-08 | 43959.03 | 未披露 | 定期报告 | 2021-11-05 |
| 2021-11-08 | 40367.32 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock in July, August and September 2021 under At-the-market offering, net of transactional expenses of $389
Issuance of common stock under 2021 Purchase Agreement
Employee stock purchase plan
|
2021-09-30 |
| 2021-08-09 | 35752.16 | 未披露 | 定期报告 | 2021-08-09 |
| 2021-08-09 | 34635.85 | 未披露 |
更多>>
from March 31, 2021 to June 30, 2021
Issuance of common stock in April and June 2021 under At-the-market offering, net of transactional expenses of $612
Issuance of commitment shares under 2021 Purchase Agreement
Issuance of common stock under 2021 Purchase Agreement
Issuance of common stock in the acquisition of the OyaGen license
|
2021-06-30 |
| 2021-05-14 | 32926.14 | 未披露 | 定期报告 | 2021-05-13 |
| 2021-04-23 | 32650.91 | 未披露 | 定期报告 | 2021-04-22 |
| 2021-05-10 | 32391.77 | 未披露 |
更多>>
From December 31, 2020 To March 31, 2021
Issuance of common stock upon exercise of warrants in March 2021 ($0.57 per share)Issuance of common stock in January 2021 ($0.80 per share), net of transactional expenses of $3,096
Issuance of common stock in February 2021 ($1.20 per share), net of transactional expenses of $5,002
Issuance of common stock under at-the-market offering, net of transactional expenses of $230
Employee stock purchase plan
|
2021-03-31 |
| 2021-03-31 | 32391.77 | 未披露 | 定期报告 | 2021-03-12 |
| 2021-02-09 | 32391.43 | 未披露 |
更多>>
1.Common Stock offered by the company in this offering 58,333,334 shares.
2.The number of shares of Common Stock to be outstanding after this offering is based on 265,580,997 shares of Common Stock outstanding at February 5, 2021.
|
2021-02-09 |
| 2021-02-09 | 26558.10 | 未披露 | 定期报告 | 2021-02-05 |
| 2021-01-13 | 26477.73 | 未披露 |
更多>>
1.Common Stock offered by the company in this offering 50,000,000 shares.
2.The number of shares of Common Stock to be outstanding after this offering is based on 214,777,250 shares of Common Stock outstanding at January 8, 2021.
|
2021-01-13 |
| 2021-01-12 | 21477.73 | 未披露 | 定期报告 | 2021-01-08 |
| 2021-03-15 | 20600.87 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share)
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711)
Issuance of common stock and common stock warrants in February 2020 net of transactional expenses of $292
Issuance of common stock upon conversion of Series B Convertible preferred stock
Issuance of common stock in March 2020 net of transactional expenses of $1,221
Issuance of common stock in June 2020 under the equity line
Issuance of common stock under At-the-market offering, net of transaction expenses of $2,304
Issuance of common stock in the acquisition of Trigemina assets
Issuance of common stock in July 2020 net of transactional expenses of $829
Issuance of common stock in exchange for exercise of warrants in July and August 2020
Issuance commitment under 2020 Purchase Agreement
Issuance of common stock under 2020 Purchase Agreement
Employee stock purchase plan
|
2020-12-31 |
| 2020-12-18 | 19164.83 | 未披露 | 定期报告 | 2020-12-17 |
| 2020-11-09 | 15658.51 | 未披露 | 定期报告 | 2020-11-06 |
| 2020-11-09 | 14015.95 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock in July 2020, net of transaction expenses of $829
Issuance of common stock in September 2020 under At-the-market offering, net of transactional expenses of $267
Issuance of common stock in exchange for exercise of warrants in July and August 2020
Issuance of commitment shares under 2020 Purchase Agreement
|
2020-09-30 |
| 2020-09-04 | 13027.73 | 未披露 | 定期报告 | 2020-09-02 |
| 2020-08-10 | 13027.37 | 未披露 | 定期报告 | 2020-08-07 |
| 2020-07-15 | 12574.39 | 未披露 |
更多>>
1.Common Stock offered by the company in this offering 20,940,000 shares.
2.The number of shares of Common Stock to be outstanding after this offering is based on 104,803,906 shares of Common Stock outstanding at July 10, 2020.
|
2020-07-15 |
| 2020-08-10 | 10480.39 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock under 2019 Purchase Agreement
Issuance of common stock in May and June 2020 under At-the-market offering, net of transaction expenses of $1,131
Issuance of common stock in the acquisition of Trigemina assets
|
2020-06-30 |
| 2020-05-15 | 5253.48 | 未披露 | 定期报告 | 2020-05-14 |
| 2020-05-12 | 5230.25 | 未披露 | 定期报告 | 2020-05-11 |
| 2020-05-12 | 4935.31 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711)
Issuance of common stock upon conversion of Series B Convertible preferred stock
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share)
Issuance of common stock and common stock warrants in February 2020 ($0.57 per share, net of transactional expenses of $292)
Issuance of common stock in March 2020 ($1.10 per share, net of transactional expenses of $1,221)
Employee stock purchase plan
|
2020-03-31 |
| 2020-03-24 | 4935.31 | 未披露 | 定期报告 | 2020-03-23 |
| 2020-03-03 | 4565.36 | 未披露 | 定期报告 | 2020-03-03 |
| 2020-03-30 | 3467.76 | 未披露 | 定期报告 | 2020-03-02 |
| 2020-02-28 | 3110.36 | 未披露 | 定期报告 | 2020-02-27 |
| 2020-02-11 | 2169.11 | 未披露 |
更多>>
On February 11, 2020, Tonix Pharmaceuticals Holding Corp., a Nevada corporation, (the “Company”), closed its previously announced public offering (the “Offering”) of an aggregate of (i) 3,837,000 Class A Units (the “Class A Units”), with each Class A Unit consisting of one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one share of Common Stock at an exercise price equal to $0.57 per share of Common Stock, and (ii) 5,313 Class B Units (the “Class B Units”), with each Class B Unit offered to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of the Company’s Series B Convertible Preferred Stock (the “Series B Preferred Stock”), with a stated value of $1,000 and convertible into 1,754.386 shares of Common Stock at the conversion price of $0.57 per share, and Warrants to purchase 1,754.386 shares of Common Stock at an exercise price equal to $0.57 per share of Common Stock.
|
2020-02-11 |
| 2020-02-06 | 853.31 | 未披露 | 定期报告 | 2020-02-05 |
| 2020-03-24 | 853.15 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Issuance of Series A Convertible preferred stock and common stock warrants in November 2019 ($1,000.00 per share, net of transactional expenses of $957)
Issuance of common stock upon conversion of Series A Convertible preferred stock
Issuance of common stock in exchange for exercise of warrants in March 2019 ($35.00 per share)
Issuance of common stock under 2018 Purchase Agreement
Issuance of common stock under At-the-market offering, net of transactional expenses of $1
Issuance of common stock under 2019 Purchase Agreement, net of transactional expenses of $916
Issuance of commitment shares in August 2019
Issuance of common stock and common stock warrants in November 2019 ($1.94 per share, net of transaction expenses of $128)
Issuance of common stock in exchange for exercise of cashless warrants
Employee stock purchase plan
|
2019-12-31 |
| 2019-12-13 | 402.11 | 未披露 | 定期报告 | 2019-11-22 |
| 2019-11-20 | 621.44 | 未披露 | 定期报告 | 2019-11-19 |
| 2019-11-08 | 157.52 | 未披露 | 定期报告 | 2019-11-08 |
| 2019-11-01 | 157.17 | 未披露 |
更多>>
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on November 1, 2019.
|
2019-11-01 |
| 2019-08-23 | 1571.74 | 未披露 | 定期报告 | 2019-08-22 |
| 2019-08-12 | 1536.21 | 未披露 | 定期报告 | 2019-08-08 |
| 2019-07-18 | 1533.83 | 未披露 | 定期报告 | 2019-07-18 |
| 2019-08-12 | 633.83 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Issuance of common stock under 2018 Purchase Agreement
Issuance of common stock under At-the-market offering, net of transactional expenses of $1
|
2019-06-30 |
| 2019-06-19 | 633.83 | 未披露 | 定期报告 | 2019-06-18 |
| 2019-05-13 | 608.97 | 未披露 |
更多>>
From December 31, 2018 to March 31, 2019
Issuance of common stock upon conversion of Series A Convertible preferred stock
Issuance of common stock in exchange for exercise of warrants in March 2019 ($3.50 per share)
Employee stock purchase plan
|
2019-03-31 |
| 2019-03-18 | 608.97 | 未披露 | 定期报告 | 2019-03-13 |
| 2019-03-18 | 470.37 | 未披露 | 定期报告 | 2019-03-07 |
| 2019-03-18 | 325.20 | 0.99 |
更多>>
from December 31, 2017 to December 31, 2018
Issuance of common stock related to restricted stock units
Issuance of commitment shares in October 2018 ($7.00 per share)
Issuance of common stock under 2017 Purchase Agreement, net of transactional expenses of $45
Issuance of common stock under At-the-market offering, net of transactional expenses of $212
Issuance of Series A Convertible preferred stock and common stock warrants in December 2018 ($1,000.00 per unit, net of transactional expenses of $1,159)
Issuance of common stock and common stock warrants in December 2018 ($3.50 per unit, net of transaction expenses of $353)
Issuance of common stock upon conversion of Series A Convertible preferred stock
|
2018-12-31 |
| 2018-12-03 | 152.94 | 未披露 | 定期报告 | 2018-11-29 |
| 2018-11-27 | 152.72 | 未披露 |
更多>>
Prior to the Reverse Stock Split, the Company was authorized to issue 150,000,000 shares of Common Stock. As a result of the Reverse Stock Split, the Board of Directors of Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), has approved a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-10 (the “Reverse Stock Split”). The Company anticipates that the Reverse Split will be effective at 12:01 a.m., Eastern Time, on November 28, 2018 (the “Effective Date”).Company will be authorized to issue 15,000,000 shares of Common Stock. As of November 26, 2018, there were 15,271,682 shares of Common Stock outstanding. As a result of the Reverse Stock Split, there will be approximately 1,527,169 shares of Common Stock outstanding (subject to adjustment due to the effect of rounding fractional shares into whole shares). The Reverse Stock Split will not have any effect on the stated par value of the Common Stock.
|
2018-11-28 |
| 2018-11-27 | 1527.17 | 未披露 | 定期报告 | 2018-11-26 |
| 2018-11-09 | 1420.34 | 未披露 | 定期报告 | 2018-11-08 |
| 2018-10-24 | 1348.37 | 未披露 | 定期报告 | 2018-10-23 |
| 2018-11-09 | 1048.05 | 未披露 |
更多>>
from December 31, 2017 to September 30, 2018
Issuance of common stock related to restricted stock units
Issuance of common stock under Purchase Agreement, net of transactional expenses of $45
Issuance of common stock under At-the-market offering, net of transaction expenses of $127
|
2018-09-30 |
| 2018-09-07 | 1002.38 | 未披露 | 定期报告 | 2018-09-05 |
| 2018-08-13 | 951.32 | 未披露 | 定期报告 | 2018-08-09 |
| 2018-08-13 | 881.99 | 未披露 |
更多>>
from December 31, 2017 to June 30, 2018
Issuance of common stock related to restricted stock units
Issuance of common stock under Purchase Agreement, net of transactional expenses of $45
Issuance of common stock in June 2018 under At-the-market offering, net of transactional expenses of $50
|
2018-06-30 |
| 2018-05-11 | 846.08 | 未披露 | 定期报告 | 2018-05-10 |
| 2018-05-01 | 834.08 | 未披露 | 定期报告 | 2018-04-30 |
| 2018-04-19 | 813.08 | 未披露 | 定期报告 | 2018-04-11 |
| 2018-05-11 | 801.08 | 未披露 |
更多>>
from December 31, 2017 to March 31, 2018
Issuance of common stock related to restricted stock units
Issuance of common stock in March ($3.21 per share), net of transaction expenses of $45
|
2018-03-31 |
| 2018-03-09 | 783.08 | 未披露 | 定期报告 | 2018-03-01 |
| 2018-03-09 | 783.00 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Employee stock purchase plan
Issuance of common stock related to restricted stock units
Issuance of common stock in February 2017 ($5.09 per share), March 2017 ($4.50 per share) and April 2017 ($6.55 per share), net of transaction expenses of $280
Issuance of common stock in April 2017 ($4.45 per share, net of transaction expenses of $888)
Issuance of commitment shares in September 2017 ($4.11 per share)
Issuance of common stock in exchange for exercise of warrants in April 2017 ($6.30 per share)
Issuance of common stock in October 2017 ($4.56 per share, net of transaction expenses of $15)
|
2017-12-31 |
| 2017-11-06 | 783.00 | 未披露 | 定期报告 | 2017-11-03 |
| 2017-11-06 | 758.17 | 未披露 |
更多>>
from December 31, 2016 to September 30, 2017
Employee stock purchase plan
Issuance of common stock related to restricted stock units
Issuance of common stock in February 2017 ($5.09 per share), March 2017 ($4.50 per share) and April 2017 ($6.55 per share), net of transaction expenses of $280
Issuance of common stock in April 2017 ($4.45 per share), net of transaction expenses of $888
Issuance of commitment shares in September 2017 ($4.11 per share)
Issuance of common stock in exchange for exercise of warrants in April 2017 ($6.30 per share)
|
2017-09-30 |
| 2017-09-29 | 758.17 | 未披露 | 定期报告 | 2017-09-28 |
| 2017-08-11 | 750.87 | 未披露 | 定期报告 | 2017-08-09 |
| 2017-08-11 | 749.02 | 未披露 |
更多>>
from December 31, 2016 to June 30, 2017
Employee stock purchase plan
Issuance of common stock related to restricted stock units
Issuance of common stock in February 2017 ($5.09 per share), March 2017 ($4.50 per share) and April 2017 ($6.55 per share), net of transaction expenses of $280
Issuance of common stock in April 2017 ($4.45 per share), net of transaction expenses of $888
Issuance of common stock in exchange for exercise of warrants in April 2017 ($6.30 per share)
|
2017-06-30 |
| 2017-04-13 | 748.60 | 未披露 |
更多>>
On March 30, 2017, the Company entered into an underwriting agreement with Aegis Capital Corp., as representative of the several underwriters (collectively, the “2017 Underwriters”), relating to the issuance and sale of 1,800,000 shares of the Company’s common stock, in an underwritten public offering (the “March 2017 Financing”).
|
2017-04-13 |
| 2017-05-12 | 416.08 | 未披露 |
更多>>
from December 31, 2016 to March 31, 2017
Employee stock purchase plan
Issuance of common stock related to restricted stock units
Issuance of common stock in February ($5.09 per share) and March ($4.50 per share), net of transaction expenses of $34
|
2017-03-31 |
| 2017-04-13 | 391.81 | 未披露 |
更多>>
from December 31, 2015 to March 17, 2017
Employee stock purchase plan
Issuance of common stock related to restricted stock units
Issuance of common stock in May and June 2016 ($24.00 per share), September 2016 ($7.40 per share), and October 2016 ($6.50 per share), net of transaction expenses of $280
Issuance of common stock in June 2016 ($20.00 per share), net of transaction expenses of $916
Issuance of common stock in July 2016 ($20.00 per share), net of transaction expenses of $105
Issuance of common stock in October 2016 ($5.50 per share), net of transaction costs of $585
On March 16, 2017 Tonix Pharmaceuticals Holding Corp. has approved a reverse stock split of the Company’s authorized, issued and outstanding shares of common stock, at a ratio of 1-for-10. The Company anticipates that the Reverse Split will be effective as of 12:01 a.m. on March 17, 2017.
|
2017-03-17 |
| 2017-03-16 | 4108.86 | 未披露 | 定期报告 | 2017-03-16 |
| 2016-11-10 | 3918.11 | 未披露 | 定期报告 | 2016-11-08 |
| 2016-11-10 | 2935.27 | 未披露 |
更多>>
from December 31, 2015 to September 30, 2016
Employee stock purchase plan
Issuance of common stock related to vested restricted stock units
Issuance of common stock in May and June 2016 ($2.40 per share), net of transaction expenses of $149
Issuance of common stock in June 2016 ($2.00 per share), net of transaction expenses of $916
Issuance of common stock in July 2016 ($2.00 per share), net of transaction expenses of $105
Issuance of common stock in September 2016 ($0.74 per share), net of transaction expenses of $124
|
2016-09-30 |
| 2016-08-05 | 2586.04 | 未披露 | 定期报告 | 2016-08-04 |
| 2016-08-05 | 2507.95 | 未披露 |
更多>>
from December 31, 2015 to June 30, 2016
Employee stock purchase plan
Issuance of common stock related to restricted stock units
Issuance of common stock in May and June 2016 ($2.40 per share), net of transaction expenses of $149
Issuance of common stock in June 2016 ($2.00 per share), net of transaction expenses of $916
|
2016-06-30 |
| 2016-05-06 | 1889.13 | 未披露 |
更多>>
from December 31, 2015 to March 31, 2016
Employee stock purchase plan
Issuance of common stock related to restricted stock units
|
2016-03-31 |
| 2016-03-25 | 1887.93 | 未披露 | 定期报告 | 2016-03-15 |
| 2016-03-03 | 1887.33 | 未披露 | 定期报告 | 2016-03-02 |
| 2015-11-06 | 1883.17 | 未披露 |
更多>>
from December 31, 2014 to September 30, 2015
Issuance of common stock in February 2015 ($5.85 per share) net of transaction expenses of $2,115
Issuance of common stock in July 2015 ($7.50 per share) net of transaction expenses of $1,369
Issuance of common stock in exchange for exercise of warrants ($4.25 per share)
Employee stock purchase plan
|
2015-09-30 |
| 2015-08-07 | 1882.97 | 未披露 | 定期报告 | 2015-08-06 |
| 2015-05-08 | 1613.79 | 未披露 |
更多>>
from December 31, 2014 to March 31, 2015
Issuance of common stock in February 2015 ($5.85 per share) net of transaction expenses of $2,061
Issuance of common stock under employee benefit plan
|
2015-03-31 |
| 2015-02-27 | 1613.79 | 未披露 | 定期报告 | 2015-02-25 |
| 2015-02-27 | 1080.52 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Issuance of common stock in exchange for exercise of warrants ($4.25 per share)Issuance of common stock in January 2014 ($15.00 per share) net of transaction expenses of $2,824
Issuance of common stock in July 2014 ($11.90 per share) net of transaction expenses of $63
Issuance of common stock to acquire intellectual property rights from related party in March 2014 ($12.15 per share)
Issuance of common stock in exchange for 48,240 warrants exercised on a cashless basis
|
2014-12-31 |
| 2014-11-07 | 1077.17 | 未披露 | 定期报告 | 2014-11-06 |
| 2014-11-07 | 1073.40 | 未披露 |
更多>>
from January 1, 2014 to September 30, 2014
Issuance of common stock in exchange for exercise of warrants ($4.25 per share)
Issuance of common stock in January 2014 ($15.00 per share), net of transactio expenses of $2,824
Issuance of common stock in July 2014 ($11.90 per share), net of transaction expenses of $636
Issuance of common stock to acquire intellectual property rights from related
party in March 2014 ($12.15 per share)
Issuance of common stock in exchange for 48,240 warrants exercised on a cashless basis
|
2014-09-30 |
| 2014-08-01 | 1059.01 | 未披露 | 定期报告 | 2014-07-31 |
| 2014-08-08 | 993.31 | 未披露 |
更多>>
from December 31, 2013 to June 30, 2014
Issuance of common stock in exchange for exercise of warrants ($4.25 per share)
Issuance of common stock in January 2014 ($15.00 per share) net of transaction expenses of $2,824
Issuance of common stock to acquire intellectual property rights from related party in March 2014 ($12.15 per share)
|
2014-06-30 |
| 2014-05-13 | 992.92 | 未披露 | 定期报告 | 2014-05-12 |
| 2014-05-13 | 990.24 | 未披露 |
更多>>
from January 1, 2014 to March 31, 2014
Issuance of common stock in exchange for exercise of warrants ($4.25 per share)Issuance of common stock in January 2014 ($15.00 per share) net of transaction expenses of $2,824
Issuance of common stock to acquire intellectual property rights from related party in March 2014 ($12.15 per share)
|
2014-03-31 |
| 2014-03-28 | 989.95 | 未披露 | 定期报告 | 2014-03-24 |
| 2014-03-28 | 582.31 | 未披露 |
更多>>
from December 31,2012 to December 31,2013
Issuance of common stock in exchange for exercise of warrants in April 2013 ($8.00 per share)
Issuance of common stock and warrants in August 2013 ($4.25 per share) net of transaction expenses of $1,352
Common stock issued (873,885) or to be issued (11,002) in exchange for exercise of warrants in December 2013 ($4.25 per share)
Issuance of common stock in exchange for exercise of warrants in December 2013 ($8.00 per share)
Issuance of common stock in exchange for 3,185 warrants exercised on a cashless basis
|
2013-12-31 |
| 2013-12-31 | 581.44 | 未披露 | 定期报告 | 2013-12-30 |
| 2013-11-13 | 487.75 | 未披露 |
更多>>
from December 31, 2012 to August 09, 2013
Issuance of common stock on exercise of warrants in April 2013 ($8.00 per share)
Issuance of common stock and warrants in August 2013 ($4.25 per share) net of transaction expenses of $1,351,987
1-for-20 reverse stock split of our outstanding common stock that was effected on May 1, 2013
|
2013-08-09 |
| 2013-08-14 | 219.75 | 未披露 |
更多>>
from December 31, 2012 to May 9, 2013
Issuance of common stock in exchange for exercise of warrants in April 2013 ($8.00 per share)
|
2013-05-09 |
Common stock offered 10,766,666 shares by the company
From December 31, 2022 to December 31, 2023
Repurchase of common stock under Share Repurchase Program, including transactional expenses of $334
Issuance of common stock under 2022 Purchase agreement
Issuance of common stock under At-the-market offering, net of transactional expenses of $137
Issuance of common stock and warrants under AGP Financing, net of transactional expenses of $2,663
Issuance of common stock upon exercise of prefunded common warrants
Employee stock purchase plan
Common stock offered 25,343,242 shares by the company
Common Stock offered 4,050,000 shares by the company
From June 30, 2023 to September 30, 2023
Issuance of common stock under AGP Financing, net of transactional expenses of $726
Issuance of common stock upon exercise of prefunded warrants under AGP Financing
Common Stock offered 2,530,000 shares of Common Stock by the company
From March 31, 2023 to June 30, 2023
Issuance of common stock net of transactional expenses of $36
Tonix Pharmaceuticals Holding Corp. announced that it will effect a 1-for-6.25 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on May 10, 2023.
From December 31, 2022 to March 31, 2023
Repurchase of common stock under share repurchase program, including transactional expenses of $334
Issuance of common stock under 2022 Purchase agreement with Lincoln Park
Issuance of common stock net of transactional expenses of $101
Employee stock purchase plan
From December 31, 2021 to December 31, 2022
Issuance of common stock under At-the-market offering, net of transactional expenses of $3,078
Issuance of common stock under 2022 Purchase Agreement
Issuance of common stock under 2021 Purchase Agreement
Issuance of commitment shares under 2022 Purchase agreement
Employee stock purchase plan
From June 30, 2022 to September 30, 2022
Issuance of common stock under the 2021 Purchase agreement
Issuance of common stock in July, August and September 2022 under At-the-market offering, net of transactional expenses of $805
Issuance of commitment shares under 2022 Purchase Agreement
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on May 17, 2022.
From December 31, 2021 to March 31, 2022
Issuance of common stock in January and March 2022, net of transactional expenses of $507
Issuance of common stock under Purchase agreement with Lincoln Park
Employee stock purchase plan
From December 31, 2020 to December 31, 2021
Issuance of common stock in January 2021($0.80 per share), net of transactional expenses of $3,096
Issuance of common stock in exchange for exercise of warrants in March 2021 ($0.57 per share)
Issuance of common stock in February 2021($1.20 per share), net of transactional expenses of $5,002
Issuance of common stock under At-the-market offering, net of transactional expenses of $2,332
Issuance of common stock under 2021 Purchase Agreement, net of transactional expenses of $75
Issuance of commitment shares under 2021 Purchase agreement
Issuance of common stock in the acquisition of the OyaGen license
Issuance of commitment shares under Lincoln park Purchase agreement
Employee stock purchase plan
From June 30, 2021 to September 30, 2021
Issuance of common stock in July, August and September 2021 under At-the-market offering, net of transactional expenses of $389
Issuance of common stock under 2021 Purchase Agreement
Employee stock purchase plan
from March 31, 2021 to June 30, 2021
Issuance of common stock in April and June 2021 under At-the-market offering, net of transactional expenses of $612
Issuance of commitment shares under 2021 Purchase Agreement
Issuance of common stock under 2021 Purchase Agreement
Issuance of common stock in the acquisition of the OyaGen license
From December 31, 2020 To March 31, 2021
Issuance of common stock upon exercise of warrants in March 2021 ($0.57 per share)Issuance of common stock in January 2021 ($0.80 per share), net of transactional expenses of $3,096
Issuance of common stock in February 2021 ($1.20 per share), net of transactional expenses of $5,002
Issuance of common stock under at-the-market offering, net of transactional expenses of $230
Employee stock purchase plan
1.Common Stock offered by the company in this offering 58,333,334 shares.
2.The number of shares of Common Stock to be outstanding after this offering is based on 265,580,997 shares of Common Stock outstanding at February 5, 2021.
1.Common Stock offered by the company in this offering 50,000,000 shares.
2.The number of shares of Common Stock to be outstanding after this offering is based on 214,777,250 shares of Common Stock outstanding at January 8, 2021.
From December 31, 2019 to December 31, 2020
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share)
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711)
Issuance of common stock and common stock warrants in February 2020 net of transactional expenses of $292
Issuance of common stock upon conversion of Series B Convertible preferred stock
Issuance of common stock in March 2020 net of transactional expenses of $1,221
Issuance of common stock in June 2020 under the equity line
Issuance of common stock under At-the-market offering, net of transaction expenses of $2,304
Issuance of common stock in the acquisition of Trigemina assets
Issuance of common stock in July 2020 net of transactional expenses of $829
Issuance of common stock in exchange for exercise of warrants in July and August 2020
Issuance commitment under 2020 Purchase Agreement
Issuance of common stock under 2020 Purchase Agreement
Employee stock purchase plan
From June 30, 2020 to September 30, 2020
Issuance of common stock in July 2020, net of transaction expenses of $829
Issuance of common stock in September 2020 under At-the-market offering, net of transactional expenses of $267
Issuance of common stock in exchange for exercise of warrants in July and August 2020
Issuance of commitment shares under 2020 Purchase Agreement
1.Common Stock offered by the company in this offering 20,940,000 shares.
2.The number of shares of Common Stock to be outstanding after this offering is based on 104,803,906 shares of Common Stock outstanding at July 10, 2020.
From March 31, 2020 to June 30, 2020
Issuance of common stock under 2019 Purchase Agreement
Issuance of common stock in May and June 2020 under At-the-market offering, net of transaction expenses of $1,131
Issuance of common stock in the acquisition of Trigemina assets
From December 31, 2019 to March 31, 2020
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711)
Issuance of common stock upon conversion of Series B Convertible preferred stock
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share)
Issuance of common stock and common stock warrants in February 2020 ($0.57 per share, net of transactional expenses of $292)
Issuance of common stock in March 2020 ($1.10 per share, net of transactional expenses of $1,221)
Employee stock purchase plan
On February 11, 2020, Tonix Pharmaceuticals Holding Corp., a Nevada corporation, (the “Company”), closed its previously announced public offering (the “Offering”) of an aggregate of (i) 3,837,000 Class A Units (the “Class A Units”), with each Class A Unit consisting of one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and one warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one share of Common Stock at an exercise price equal to $0.57 per share of Common Stock, and (ii) 5,313 Class B Units (the “Class B Units”), with each Class B Unit offered to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of the Company’s Series B Convertible Preferred Stock (the “Series B Preferred Stock”), with a stated value of $1,000 and convertible into 1,754.386 shares of Common Stock at the conversion price of $0.57 per share, and Warrants to purchase 1,754.386 shares of Common Stock at an exercise price equal to $0.57 per share of Common Stock.
From December 31, 2018 to December 31, 2019
Issuance of Series A Convertible preferred stock and common stock warrants in November 2019 ($1,000.00 per share, net of transactional expenses of $957)
Issuance of common stock upon conversion of Series A Convertible preferred stock
Issuance of common stock in exchange for exercise of warrants in March 2019 ($35.00 per share)
Issuance of common stock under 2018 Purchase Agreement
Issuance of common stock under At-the-market offering, net of transactional expenses of $1
Issuance of common stock under 2019 Purchase Agreement, net of transactional expenses of $916
Issuance of commitment shares in August 2019
Issuance of common stock and common stock warrants in November 2019 ($1.94 per share, net of transaction expenses of $128)
Issuance of common stock in exchange for exercise of cashless warrants
Employee stock purchase plan
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on November 1, 2019.
From March 31, 2019 to June 30, 2019
Issuance of common stock under 2018 Purchase Agreement
Issuance of common stock under At-the-market offering, net of transactional expenses of $1
From December 31, 2018 to March 31, 2019
Issuance of common stock upon conversion of Series A Convertible preferred stock
Issuance of common stock in exchange for exercise of warrants in March 2019 ($3.50 per share)
Employee stock purchase plan
from December 31, 2017 to December 31, 2018
Issuance of common stock related to restricted stock units
Issuance of commitment shares in October 2018 ($7.00 per share)
Issuance of common stock under 2017 Purchase Agreement, net of transactional expenses of $45
Issuance of common stock under At-the-market offering, net of transactional expenses of $212
Issuance of Series A Convertible preferred stock and common stock warrants in December 2018 ($1,000.00 per unit, net of transactional expenses of $1,159)
Issuance of common stock and common stock warrants in December 2018 ($3.50 per unit, net of transaction expenses of $353)
Issuance of common stock upon conversion of Series A Convertible preferred stock
Prior to the Reverse Stock Split, the Company was authorized to issue 150,000,000 shares of Common Stock. As a result of the Reverse Stock Split, the Board of Directors of Tonix Pharmaceuticals Holding Corp., a Nevada corporation (the “Company”), has approved a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a ratio of 1-for-10 (the “Reverse Stock Split”). The Company anticipates that the Reverse Split will be effective at 12:01 a.m., Eastern Time, on November 28, 2018 (the “Effective Date”).Company will be authorized to issue 15,000,000 shares of Common Stock. As of November 26, 2018, there were 15,271,682 shares of Common Stock outstanding. As a result of the Reverse Stock Split, there will be approximately 1,527,169 shares of Common Stock outstanding (subject to adjustment due to the effect of rounding fractional shares into whole shares). The Reverse Stock Split will not have any effect on the stated par value of the Common Stock.
from December 31, 2017 to September 30, 2018
Issuance of common stock related to restricted stock units
Issuance of common stock under Purchase Agreement, net of transactional expenses of $45
Issuance of common stock under At-the-market offering, net of transaction expenses of $127
from December 31, 2017 to June 30, 2018
Issuance of common stock related to restricted stock units
Issuance of common stock under Purchase Agreement, net of transactional expenses of $45
Issuance of common stock in June 2018 under At-the-market offering, net of transactional expenses of $50
from December 31, 2017 to March 31, 2018
Issuance of common stock related to restricted stock units
Issuance of common stock in March ($3.21 per share), net of transaction expenses of $45
from December 31, 2016 to December 31, 2017
Employee stock purchase plan
Issuance of common stock related to restricted stock units
Issuance of common stock in February 2017 ($5.09 per share), March 2017 ($4.50 per share) and April 2017 ($6.55 per share), net of transaction expenses of $280
Issuance of common stock in April 2017 ($4.45 per share, net of transaction expenses of $888)
Issuance of commitment shares in September 2017 ($4.11 per share)
Issuance of common stock in exchange for exercise of warrants in April 2017 ($6.30 per share)
Issuance of common stock in October 2017 ($4.56 per share, net of transaction expenses of $15)
from December 31, 2016 to September 30, 2017
Employee stock purchase plan
Issuance of common stock related to restricted stock units
Issuance of common stock in February 2017 ($5.09 per share), March 2017 ($4.50 per share) and April 2017 ($6.55 per share), net of transaction expenses of $280
Issuance of common stock in April 2017 ($4.45 per share), net of transaction expenses of $888
Issuance of commitment shares in September 2017 ($4.11 per share)
Issuance of common stock in exchange for exercise of warrants in April 2017 ($6.30 per share)
from December 31, 2016 to June 30, 2017
Employee stock purchase plan
Issuance of common stock related to restricted stock units
Issuance of common stock in February 2017 ($5.09 per share), March 2017 ($4.50 per share) and April 2017 ($6.55 per share), net of transaction expenses of $280
Issuance of common stock in April 2017 ($4.45 per share), net of transaction expenses of $888
Issuance of common stock in exchange for exercise of warrants in April 2017 ($6.30 per share)
On March 30, 2017, the Company entered into an underwriting agreement with Aegis Capital Corp., as representative of the several underwriters (collectively, the “2017 Underwriters”), relating to the issuance and sale of 1,800,000 shares of the Company’s common stock, in an underwritten public offering (the “March 2017 Financing”).
from December 31, 2016 to March 31, 2017
Employee stock purchase plan
Issuance of common stock related to restricted stock units
Issuance of common stock in February ($5.09 per share) and March ($4.50 per share), net of transaction expenses of $34
from December 31, 2015 to March 17, 2017
Employee stock purchase plan
Issuance of common stock related to restricted stock units
Issuance of common stock in May and June 2016 ($24.00 per share), September 2016 ($7.40 per share), and October 2016 ($6.50 per share), net of transaction expenses of $280
Issuance of common stock in June 2016 ($20.00 per share), net of transaction expenses of $916
Issuance of common stock in July 2016 ($20.00 per share), net of transaction expenses of $105
Issuance of common stock in October 2016 ($5.50 per share), net of transaction costs of $585
On March 16, 2017 Tonix Pharmaceuticals Holding Corp. has approved a reverse stock split of the Company’s authorized, issued and outstanding shares of common stock, at a ratio of 1-for-10. The Company anticipates that the Reverse Split will be effective as of 12:01 a.m. on March 17, 2017.
from December 31, 2015 to September 30, 2016
Employee stock purchase plan
Issuance of common stock related to vested restricted stock units
Issuance of common stock in May and June 2016 ($2.40 per share), net of transaction expenses of $149
Issuance of common stock in June 2016 ($2.00 per share), net of transaction expenses of $916
Issuance of common stock in July 2016 ($2.00 per share), net of transaction expenses of $105
Issuance of common stock in September 2016 ($0.74 per share), net of transaction expenses of $124
from December 31, 2015 to June 30, 2016
Employee stock purchase plan
Issuance of common stock related to restricted stock units
Issuance of common stock in May and June 2016 ($2.40 per share), net of transaction expenses of $149
Issuance of common stock in June 2016 ($2.00 per share), net of transaction expenses of $916
from December 31, 2015 to March 31, 2016
Employee stock purchase plan
Issuance of common stock related to restricted stock units
from December 31, 2014 to September 30, 2015
Issuance of common stock in February 2015 ($5.85 per share) net of transaction expenses of $2,115
Issuance of common stock in July 2015 ($7.50 per share) net of transaction expenses of $1,369
Issuance of common stock in exchange for exercise of warrants ($4.25 per share)
Employee stock purchase plan
from December 31, 2014 to March 31, 2015
Issuance of common stock in February 2015 ($5.85 per share) net of transaction expenses of $2,061
Issuance of common stock under employee benefit plan
from December 31, 2013 to December 31, 2014
Issuance of common stock in exchange for exercise of warrants ($4.25 per share)Issuance of common stock in January 2014 ($15.00 per share) net of transaction expenses of $2,824
Issuance of common stock in July 2014 ($11.90 per share) net of transaction expenses of $63
Issuance of common stock to acquire intellectual property rights from related party in March 2014 ($12.15 per share)
Issuance of common stock in exchange for 48,240 warrants exercised on a cashless basis
from January 1, 2014 to September 30, 2014
Issuance of common stock in exchange for exercise of warrants ($4.25 per share)
Issuance of common stock in January 2014 ($15.00 per share), net of transactio expenses of $2,824
Issuance of common stock in July 2014 ($11.90 per share), net of transaction expenses of $636
Issuance of common stock to acquire intellectual property rights from related
party in March 2014 ($12.15 per share)
Issuance of common stock in exchange for 48,240 warrants exercised on a cashless basis
from December 31, 2013 to June 30, 2014
Issuance of common stock in exchange for exercise of warrants ($4.25 per share)
Issuance of common stock in January 2014 ($15.00 per share) net of transaction expenses of $2,824
Issuance of common stock to acquire intellectual property rights from related party in March 2014 ($12.15 per share)
from January 1, 2014 to March 31, 2014
Issuance of common stock in exchange for exercise of warrants ($4.25 per share)Issuance of common stock in January 2014 ($15.00 per share) net of transaction expenses of $2,824
Issuance of common stock to acquire intellectual property rights from related party in March 2014 ($12.15 per share)
from December 31,2012 to December 31,2013
Issuance of common stock in exchange for exercise of warrants in April 2013 ($8.00 per share)
Issuance of common stock and warrants in August 2013 ($4.25 per share) net of transaction expenses of $1,352
Common stock issued (873,885) or to be issued (11,002) in exchange for exercise of warrants in December 2013 ($4.25 per share)
Issuance of common stock in exchange for exercise of warrants in December 2013 ($8.00 per share)
Issuance of common stock in exchange for 3,185 warrants exercised on a cashless basis
from December 31, 2012 to August 09, 2013
Issuance of common stock on exercise of warrants in April 2013 ($8.00 per share)
Issuance of common stock and warrants in August 2013 ($4.25 per share) net of transaction expenses of $1,351,987
1-for-20 reverse stock split of our outstanding common stock that was effected on May 1, 2013
from December 31, 2012 to May 9, 2013
Issuance of common stock in exchange for exercise of warrants in April 2013 ($8.00 per share)